2013 was a banner year for the life sciences sector, with biotech,
pharmaceutical, and medtech companies buoyed by advances in therapeutic
techniques, a friendly regulatory environment, lucrative partnerships
and the overall market upswing.
The 2013 Biotech Watchlist reflected this robustness, boasting a
year-to-date return that blew past those posted by the major indices.
Credit the basket of stocks picked by industry experts, weighted heavily
with winners.
Can our panel of experts pick another winning portfolio in 2014? Find
out which companies they've chosen for the 2014 Watchlist in this
exclusive from The Life Sciences Report. (more)
Please share this article
No comments:
Post a Comment